Lupin 2023

Annual Cortellis “Drugs to Watch List” identifies eleven new blockbusters forecast to launch in 2020

Print Friendly, PDF & Email

PHILADELPHIA — Clarivate Analytics, a global leader in providing trusted insights and analytics to accelerate the pace of innovation, Monday announced  the launch of its annual Cortellis “Drugs to Watch ” list which identifies eleven new drugs scheduled to enter the market in 2020 predicted to achieve annual sales of $1 billion or more (i.e., blockbuster status) by 2024.

The list and therapeutic analyses focus on the treatment and even cure, of chronic, progressive and often debilitating diseases and conditions, including breast cancer (2), type 2 diabetes, migraine and multiple sclerosis (2).

The drugs listed are almost universally accelerated in their development by orphan drug status or other designation intended to speed up their path to market. There is a high level of expectation of commercial success for each of these drugs – despite the fact that most medicines on the list are entering or are poised to enter markets already crowded with competitors, meaning they’ll face substantial pressures to differentiate themselves. Many are expected to tout improved safety vs. alternative therapies, especially around cardiovascular risk, while others will seek to highlight novel mechanisms of action or even curative potential.

More than half of the medicines on the list are biologics, a fast-growing and increasingly expensive segment of prescription medicine for which regulators and payers alike have sought to rein in costs during recent years. Gene and cell therapies – represented on this year’s list by hemophilia A therapy Valrox (Biomarin Pharmaceutical Inc.) and lisocabtagene maraleucel (Bristol-Myers Squibb Co.) for large B-cell lymphoma, respectively – have drawn particular attention for their budget-busting potential.

If approved, Valrox will be crowned as the first potential curative approach for severe hemophilia A. The one-and-done therapy will be transformative as it corrects the genetic defect underlying the condition and eliminates the need for blood transfusions and FVIII replacement therapy. If, as expected it takes a leadership position it could become the most expensive drug ever to reach the market with a cost of $2.5m – 3m per treatment.

Full list available here:


Comments are closed.